Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Inclusion Criteria

• •Patients must be able to provide informed consent according to institutional guidelines
• •Patients must have: 1) MCL; or 2) relapsed or refractory cluster of differentiation (CD)20 positive B-cell indolent NHL; or 3) relapsed CLL
• •Patients must have measurable disease/disease status requirements as follows:
• •For CLL patients, symptomatic disease as defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria that mandate treatment
• •For B-cell NHL patients must have at least one of the following to be eligible:
• •* Positron emission tomography (PET) avid or measurable disease by computed tomography (CT) scan defined as at least 1 lesion that measures \> 2 cm in a single dimension
• •* Significant bone marrow and/or peripheral blood involvement by NHL (i.e. leukemic phase) as determined by the investigator
• •* Patients with Waldenström macroglobulinemia (WM) are exempt from this requirement if they have symptomatic hyperviscosity or clinically relevant cytopenias and elevated serum immunoglobulin M (IgM)
• •Patients must have adequate bone marrow reserve as indicated by an absolute neutrophil count (ANC) \> 1.500/mm\^3 and platelet count \> 150.000/mm\^3 if no bone marrow involvement; however, if there is significant lymphoma/leukemia bone marrow infiltration, no pre-existing hematologic parameters must be met
• •Patients must have a performance status of 0, 1, or 2 according to Eastern Cooperative Oncology Group
• •Serum creatinine \< 2.0 mg/dL or estimated glomerular filtration rate (GFR) \> 60 mL/min
• •Serum bilirubin =\< 1.5 × upper limit of normal (ULN)
• •Aspartate transaminase (AST)/alanine transaminase (ALT) =\< 2.5 × ULN
• •Alkaline phosphatase =\< 2.5 × ULN
• •Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment
• •Male and female patients must agree to use an effective contraceptive method during the study and for a minimum of 6 months after study treatment